Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Onxeo Reports First-Half 2017 Results And Business Update July 30, 2017 Masimo Announces CE Marking Of Rad-97 Pulse CO-Oximeter And Connectivity Hub With Noninvasive Blood Pressure March 19, 2017 Compugen Ltd. Provides Update On COM701 And Upcoming Presentations May 30, 2017
Masimo Announces CE Marking Of Rad-97 Pulse CO-Oximeter And Connectivity Hub With Noninvasive Blood Pressure March 19, 2017
